New therapeutical approaches for treatment of irritable bowel syndrome;Neue therapieansätze zur behandlung des reizdarmsyndroms

Medizinische Monatsschrift fur Pharmazeuten

Volumn 33, Issue 8, 2010, Pages

  Siegert, Fritzi ^a   Nieber, Karen ^a  

^a Institut fur Pharmazie   (Germany)

Author keywords

Irritable bowel syndrome; Linaclotide; Lubiprostone; Pain; ROM III criteria; Serotonin receptor ligands

Indexed keywords

AMITRIPTYLINE; BISACODYL; CHLORIDE CHANNEL; CITALOPRAM; FLUOXETINE; FLUSPIRILENE; GUANYLATE CYCLASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; IBEROGAST; IMIPRAMINE; ISPAGULA; LACTULOSE; LINACLOTIDE; LIPOCOL MERZ; LOPERAMIDE; LUBIPROSTONE; MACROGOL 3350; MEBEVERINE; MEDACALM; MUTAFLOR; PRUCALOPRIDE; RAMOSETRON; RENZAPRIDE; SCOPOLAMINE BUTYL BROMIDE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SIMETHICONE; SULPIRIDE; TEGASEROD; TRIHEXYPHENIDYL; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG; GUANYLATE CYCLASE; SEROTONIN ANTAGONIST;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; BLOATING; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL MOTILITY DISORDER; HEART FUNCTION; HUMAN; IRRITABLE COLON; REVIEW; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM;

CHLORIDE CHANNELS; ENZYME ACTIVATION; GUANYLATE CYCLASE; HUMANS; IRRITABLE BOWEL SYNDROME; SEROTONIN ANTAGONISTS;

EID: 78649902402     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Talley NJ. Irritable bowel syndrome. Intern Med J 2006;36:724-8.
2. Adeyemo MA, Chang Lin. New treatments for irritable bowel syndrome in women. Womens Health (Lond Engl) 2008;4:605-23.
3. Hotz J, Enck P, Goebell H, Heymann-Mönnikes I, et al. Konsensusbericht: Reizdarmsyndrom - Definition, Diagnosesicherung, Pathophysiologie und Therapiemöglichkeiten. Konsensus der Deutschen Gesellschaft für Stoffwechsel- und Verdauungskrankheiten. Z Gastroenterol 1999;37:685-700.
4. Gale JD. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Adv Ther 2009;26:519-30.
5. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-54.
6. Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003;67:82-9.
7. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharacol Ther 2009;29:315-28.
8. Tack J, van Outryve M, Beyens G, Kerstens R, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58:357-65.
9. Sanger GJ. Translating 5-HT4 receptor pharmacology. Neurogastroenterol Motil 2009;21:1235-8.
10. Smith JAM, Beattie DT, Marquess D, Shaw J-P, et al. The in vitro pharmacological profile of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity. Naunyn-Schmiedeberg's Arch Pharmacol 2008;378:125-37.
11. Beattie DT, Armstrong SR, Shaw J-P, Marquess D, et al. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity. Naunyn-Schmiedeberg's Arch Pharmacol 2008;378:139-47.
12. Manini ML, Camilleri M, Goldberg M, Sweetser S, et al. Effects of velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010;22:42-e8.
13. Baker DE. Rationale for using serotonergic agents to treat irritable bowel syndrome. Am J Health Syst Pharm 2005;62:700-11.
14. Fayyaz M, Lackner JM. Serotonin receptor modulators in the treatment of irritable bowel syndrome. Ther Clin Risk Manag 2008;4:41-8.
15. Funatsu T, Takeuchi A, Hirata T, Keto Y, et al. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. Eur J Pharmacol 2007;573:190-5.
16. Yamano M, Ito H, Kamato T, Miyata K. Characteristics if inhibitory effects of serotonin (5HT)3-receptor antagonists, YM060 and YM114 (KAE-393), on the von Bezold-Jarish reflex induced by 2-Methyl-5-HT, veratridine and electrical stimulation of vagus nerves in anesthetized rats. Jpn J Pharmacol 1995;69:351-6.
17. Hirata T, Funatsu T, Keto Y, Akuzawa S, et al. Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents. J Pharmacol Sci 2008;106:264-70.
18. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, et al. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008;77:225-35.
19. Briejer MR, Akkermans LM, Schuurkes JA. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995;47:631-51.
20. Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004;2:895-904.
21. Tack J, Middleton SJ, Horne MC, Piessevaux H, et al. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:1655-65.
22. George AM, Meyers NL, Hickling RI. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome - multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther 2008;27:830-7.
23. Firmeninformation auf http://drugs.com/clinical-trials/results- renzapride-phase-iii-clinical-trial-4052.html
24. Lacy BE, Levy LC. Lubiprostone: a chloride channel activator. J Clin Gastroenterol 2007;41:345-51.
25. Blikslager AT, Moeser AJ, Gookin JL, Jones SL, et al. Restoration of barrier function in injured intestinal mucosa. Physiol Rev 2007;87:545-64.
26. Johanson JF, Drossman DA, Pana R, Wahle A, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Liment Pharmacol Ther 2008;27:685-96.
27. Drossman DA, Chey WD, Johanson JF, Fass R, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-41.
28. Andresen V, Camilleri M, Busciglio IA, Grudell A, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8.
29. Johnston JM, MacDougall JE, Lavins BJ, Fitch DA, et al. Linaclotide significantly improved abdominal pain/discomfort and global assessments in adults with irritable bowel syndrome with constipation. Neurogastroenterol Motil 2008;20(Suppl 2):13 (Abstract).
30. Johnstorn JM, Kurtz CB, Drossman DA, Lembo AJ, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009;104:125-32.
31. Firmeninformation auf www.drugs.com/clinical-trials/ironwood-forest- announce-positive-linaclotide-results-two-pivotal-phase-3-trials-patients- chronic-8374.html
32. Firmeninformation auf www.faqs.org/sec-filings/100120/IRONWOOD- PHARMACEUTICALS-INC-S-1.A/
33. Longstreth GF, Thompson WG, Chey WD, Houghton LA, et al. Functional Bowel Disorders. Gastroenterology 2006;130:1480-91.
34. Hotz J, Madisch A. Symptomatische Therapie von funktionellen Störungen des Magen-Darm-Trakts. In: Schölmerich J., Sewing KF (Hrsg.): Arzneimitteltherapie in der Gastroenterologie. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 2003:23-35.
35. Owyang C, Günther U, Hoffmann JC. Reizdarmsyndrom. In: Fauci, Braunwald, Kasper, Hauser, et al: Harrisons Innere Medizin. 7. Auflage. Berlin: ABW Wissenschaftsverlag, 2009:2344-8.
36. Mertz HR. Irritable bowel syndrome. N Engl J Med 2003;349:2136-46.
37. Madisch A, Holtmann G, Plein K, Hotz J. Tretament of irritable bowel syndrome with herbal preparations:results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004;19:271-9.
38. Goldberg MR, Li Y-P, Pitzer K, Johanson JF, et al. TD-5108, a selective 5HT4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation. Gastroenterology 2008;134(Suppl 1):A545.
39. Goldberg MR, Li Y-P, Mangel AW, Johanson JF, et al. In patients with chronic constipation, TD-5108, a selective 5HT4 agonist with high intrinsic activity, relieves straining, normalizes stool consistency and reduces laxative use. Gastroenterology 2008;134(Suppl 1):A547.